Home › Wegovy pill reviews and real-world results

Last reviewed Nov 15, 2026

Wegovy pill reviews

We may earn a commission from some links on this page. How we make money.

Short answer: Most people who complete treatment lose 13–17% of their body weight. Side effects are real but manageable for most people—worst at dose increases, easing at steady state. Switchers from injectables report less immediate appetite suppression but meaningful continued weight loss.

What the main trial found (OASIS 4)

OASIS 4 was the pivotal Phase 3 trial that led to FDA approval of the Wegovy pill. Adults with obesity (BMI ≥30, or ≥27 with a weight-related condition) took the Wegovy pill once daily for 64 weeks alongside lifestyle counseling.

  • 13.6% average body weight loss in the intent-to-treat population (everyone who started, including those who stopped early).
  • 16.6% average body weight loss in the on-treatment population (everyone who stayed on the medication for the full trial period).
  • 81.5% of participants completed the trial—a high completion rate compared to many drug trials.
  • About 1 in 3 participants lost ≥20% of body weight on treatment.
  • 6.9% stopped due to side effects (vs. 5.9% on placebo).

The 13.6% ITT number is the most honest benchmark—it includes everyone who started, so it reflects real-world "what happens to people who try this drug" rather than only people who had no problems. The 16.6% on-treatment number shows what most people who complete the program can expect.

Switching from an injection: the OCTANE study

Many people who already use a Wegovy injection or other GLP-1 injectable wonder whether switching to the pill makes sense. The OCTANE study (Ro, presented at EASD 2026) looked at 194 patients who switched from an injectable GLP-1 to the Wegovy pill:

  • −4.1% additional weight loss on average in the first 3 months after switching.
  • 82.4% reported at least one treatment improvement—most commonly easier travel, fewer injection-site issues, or a simpler routine.
  • Some switchers noticed the pill felt "less immediate" in its appetite-suppression effect in the first 4–8 weeks; this is consistent with the pill's dose-escalation schedule (you spend weeks building up to 25 mg).

What patients report at each stage

Patient accounts from clinical programs and online health communities describe a consistent pattern:

  • Weeks 1–4 (1.5 mg): appetite suppression may be subtle; some nausea, especially in the first few days after swallowing. Many report no dramatic effect yet.
  • Weeks 5–8 (4 mg): more noticeable reduction in hunger; nausea peaks for some people at this transition. Most describe it as manageable with adjustments (smaller meals, avoiding fatty foods).
  • Weeks 9–12 (9 mg): the step to 9 mg is where most people notice a meaningful change in appetite. Weight loss starts to accelerate.
  • Month 4 and beyond (25 mg maintenance): most weight loss occurs at this stage. Early 12-week responders tend to have better long-term outcomes (Drug Topics, May 2026).
  • Months 6–12: the peak weight-loss window. Most of the 13.6% ITT average is accumulated here.
  • Month 15–18+: weight loss plateaus for most people. This is expected and not a sign the medication stopped working.

Side effects: what people actually experience

The most common side effects reported in OASIS 4 and in real-world programs:

  • Nausea affects most people at some point—worst at dose escalation, usually improves at steady state.
  • Belching (eructation): about 14% of Wegovy pill users report this—more than with the injection form. For many people it's noticeable but not intolerable.
  • Constipation and diarrhea are common, especially in the first weeks at a new dose.
  • Skin tingling (dysesthesia): about 5% report this. It's unusual among GLP-1 medications and specific to the tablet formulation.
  • Side effects are worst during dose increases and typically ease at steady state.

What to know before starting

  • The 30-minute morning fast is non-negotiable: food and other fluids (besides up to 4 oz of plain water) reduce absorption significantly. People who find this hard often do better setting an alarm, taking the pill before getting out of bed, and keeping a small glass of water on the nightstand.
  • Weight regain is real. In the STEP 1 extension study, about two-thirds of people who stopped the injection form regained most of their weight within one year. The pill is expected to work similarly—long-term use is typically needed to maintain results.
  • Early response predicts long-term success. If you've lost ≥5% at 12 weeks, you're on track. If not, talk to your clinician—not about stopping, but about whether the dose or program needs adjustment.

Curious how the Wegovy pill compares to Foundayo on side effects? See Foundayo vs. Wegovy pill side effects compared. For the full dosing timeline, see the Wegovy pill dosing schedule.

Ready to start?

Ro and LifeMD both list the Wegovy pill and Foundayo, starting at $149/mo. Compare fees on our where-to-get page.

FAQ

How much weight do you lose on the Wegovy pill?

In the OASIS 4 trial, people lost an average of 13.6% of body weight over 64 weeks (intent-to-treat population), or 16.6% if they stayed on the drug for the full study. About 1 in 3 people on-treatment lost ≥20%.

What do people say about the Wegovy pill?

Most describe a gradual reduction in appetite that builds over the dose-escalation period. Side effects—especially nausea and belching—are most noticeable at dose increases and tend to ease at steady state. Switchers from injectables report the pill feels 'less immediate' in the first month.

How long does it take for the Wegovy pill to work?

Most people notice meaningful appetite suppression around months 2–3 (9 mg step). The largest weight-loss gains typically happen in months 4–12 at the 25 mg maintenance dose.

Does the Wegovy pill cause belching?

Yes—about 14% of users in OASIS 4 reported excessive belching. It's more common with the tablet than with the injection form of Wegovy.

What happens when you stop the Wegovy pill?

Based on the injection-form STEP 1 extension data, about two-thirds of people regain most of their lost weight within a year of stopping. Long-term use is typically needed to maintain results.

Related guides

Sources